	US 11,987,556 B2
	Dual-functional compounds and methods of use
Zheng Huang, Beijing (CN); and Tianwei Ma, Beijing (CN)
Assigned to BIOFRONT THERAPEUTICS (BEIJING) CO., LTD., Beijing (CN)
Filed by BIOFRONT THERAPEUTICS (BEIJING) CO., LTD., Beijing (CN)
Filed on Jan. 30, 2023, as Appl. No. 18/161,843.
Application 18/161,843 is a continuation of application No. PCT/CN2021/109492, filed on Jul. 30, 2021.
Claims priority of provisional application 63/058,512, filed on Jul. 30, 2020.
Prior Publication US 2023/0174482 A1, Jun. 8, 2023
Int. Cl. C07D 209/38 (2006.01); A61P 11/00 (2006.01); C07D 497/04 (2006.01)

CPC C07D 209/38 (2013.01) [A61P 11/00 (2018.01); C07D 497/04 (2013.01)]

17 Claims

1. A compound represented by formula (I):

L₁—X—L₂ (I),

wherein the compound is configured to release nitric oxide (NO) and inhibit activity of a phosphodiesterase (PDE) when administered to a subject,

wherein L₁includes a functional group that is part or all of a NO releasing agent;

L₂includes a functional group that is part or all of a PDE inhibitor, wherein L₂is

and

—X— is a covalent bond, a non-covalent bond or a biradical that connects L₁and L₂.